Growth hormone secretagogue receptor of selective ligands for the GHS-R receptor are now available and are being developed for several clinical applications. GHS-R agonists have appetite-stimulating and growth hormone-releasing effects, and are likely to be useful for the treatment of muscle wasting and frailty associated with old-age and degenerative diseases. On the other hand, GHS-R antagonists have anorectic effects and are likely to be useful for the treatment of obesity. Growth hormone secretagogue receptor Growth hormone secretagogue receptor(GHS-R), also known as ghrelin receptor, is a G protein-coupled receptor that binds growth hormone secretagogues (GHSs), such as ghrelin, the "hunger hormone". The role of GHS-R
Ghrelin promotilin and both are members of the motilin family. Unlike the case of many other endogenous peptides, ghrelin is able to cross the blood-brain-barrier, giving exogenously-administered ghrelin unique clinical potential. Ghrelin was discovered after the ghrelin receptor (called growth hormone secretagogue type 1A receptor or GHS-R) was discovered in 1996 and was reported in 1999. The hormone name is based on its role as a "growth hormone-releasing peptide", with reference to the Proto-Indo-European root "gʰre-", meaning "to grow". The "GHRL" gene produces mRNA which has four exons. Five products arise: the first is the 117-amino acid "preproghrelin". (It is homologous